HomeCompareNDEV vs ABBV

NDEV vs ABBV: Dividend Comparison 2026

NDEV yields 14285.71% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NDEV wins by $1868328188208921344.00M in total portfolio value
10 years
NDEV
NDEV
● Live price
14285.71%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1868328188208921344.00M
Annual income
$1,842,950,648,126,759,800,000,000.00
Full NDEV calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — NDEV vs ABBV

📍 NDEV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNDEVABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NDEV + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NDEV pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NDEV
Annual income on $10K today (after 15% tax)
$1,214,285.71/yr
After 10yr DRIP, annual income (after tax)
$1,566,508,050,907,746,000,000,000.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, NDEV beats the other by $1,566,508,050,907,746,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NDEV + ABBV for your $10,000?

NDEV: 50%ABBV: 50%
100% ABBV50/50100% NDEV
Portfolio after 10yr
$934164094104460672.00M
Annual income
$921,475,324,063,379,900,000,000.00/yr
Blended yield
98.64%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

NDEV
No analyst data
Altman Z
1.7
Piotroski
5/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NDEV buys
0
ABBV buys
0
No recent congressional trades found for NDEV or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNDEVABBV
Forward yield14285.71%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$1868328188208921344.00M$102.3K
Annual income after 10y$1,842,950,648,126,759,800,000,000.00$24,771.77
Total dividends collected$1866648039868218112.00M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: NDEV vs ABBV ($10,000, DRIP)

YearNDEV PortfolioNDEV Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$1,439,271$1,428,571.43$11,550$430.00+$1.43MNDEV
2$193,699,090$192,159,069.24$13,472$627.96+$193.69MNDEV
3$24,376,441,818$24,169,183,791.94$15,906$926.08+$24376.43MNDEV
4$2,868,716,750,186$2,842,633,957,441.24$19,071$1,382.55+$2868716.73MNDEV
5$315,716,708,842,374$312,647,181,919,674.60$23,302$2,095.81+$315716708.82MNDEV
6$32,495,195,455,130,188$32,157,378,576,668,850.00$29,150$3,237.93+$32495195455.10MNDEV
7$3,128,044,259,554,657,300$3,093,274,400,417,667,600.00$37,536$5,121.41+$3128044259554.62MNDEV
8$281,631,115,249,329,080,000$278,284,107,891,605,600,000.00$50,079$8,338.38+$281631115249329.00MNDEV
9$23,717,327,179,590,366,000,000$23,415,981,886,273,583,000,000.00$69,753$14,065.80+$23717327179590368.00MNDEV
10$1,868,328,188,208,921,400,000,000$1,842,950,648,126,759,800,000,000.00$102,337$24,771.77+$1868328188208921344.00MNDEV

NDEV vs ABBV: Complete Analysis 2026

NDEVStock

Novus Acquisition & Development Corp., through its subsidiary, WCIG Insurance Service, Inc., operates as an insurance company in California It offers health policies in CBD concentrate cannabis space; benefit plans, such as dental vision, hearing, and telemedicine; and THC health plans. The company was formerly known as BrandQuest Development Group, Inc. and changed its name to Novus Acquisition & Development Corp. in April 2009. Novus Acquisition & Development Corp. was incorporated in 1996 and is based in Miami, Florida.

Full NDEV Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this NDEV vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NDEV vs SCHDNDEV vs JEPINDEV vs ONDEV vs KONDEV vs MAINNDEV vs JNJNDEV vs MRKNDEV vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.